Nitrosamine Impurities: Analytical Detection and Risk Assessment

Nitrosamine impurities are organic compounds bearing the N-nitroso functional group attached to two organic substituents. Since 2018 they have drawn unprecedented regulatory and scientific attention because of their potent carcinogenicity and mutagenicity and their potential to contaminate products across many therapeutic classes (1). Their lipophilic character allows cellular membrane penetration, they remain chemically stable under standard storage, and they persist through conventional purification steps, so residual contamination can survive into the finished drug product despite manufacturing controls.

Nitrosamines are classified as Class 1, known genotoxic carcinogens under ICH M7(R1) (1,2,30), and are designated probable human carcinogens (Group 2A) by the International Agency for Research on Cancer (30). Their mechanism of carcinogenicity involves metabolic activation to reactive intermediates that form DNA adducts, producing mutagenic and chromosomal effects. Chronic exposure has been linked to tumors of the liver, lung, nasal cavity, esophagus, pancreas, stomach, bladder, colon, and kidney, and emerging data suggest possible associations with neurodegenerative and metabolic disease.

Although N-nitroso compounds were first described chemically in the 1870s, their toxicological hazard was established by Barnes and Magee in 1956, who demonstrated hepatotoxicity and carcinogenicity in animal models (18). This finding remained largely academic until July 2018, when the FDA recalled valsartan products manufactured by Zhejiang Huahai after detecting unacceptable levels of a nitrosamine contaminant (1,16,18). Recalls quickly extended to losartan and irbesartan in August 2018, affecting roughly sixteen generic manufacturers. Ranitidine was withdrawn globally in September 2019, and metformin recalls followed in December 2019. Contamination has since been identified in rifampicin, varenicline, famotidine, nizatidine, atorvastatin, bumetanide, itraconazole, enalapril, lisinopril, propranolol, duloxetine, rivaroxaban, pioglitazone, gliflozins, cilostazol, and sunitinib, among others.

These incidents exposed vulnerabilities in manufacturing quality systems, raw material sourcing, supplier oversight, and post-approval change control, and revealed that conventional HPLC-UV methods could not detect the trace-level contamination involved (4,21). The low acceptable intake limits, high toxicological potency, and variable formation pathways across manufacturing processes together demand rigorous, lifecycle-wide risk management (25). The aim of this article is to provide holistic review overcurrent nitrosamine chemistry, legislation, analytical methodologies, and risk-based control strategies to aid pharmaceutical quality professionals involved in nitrosamine monitoring and mitigation.

2. CHEMISTRY OF NITROSAMINE IMPURITIES

2.1 Structure and classification

Nitrosamines carry the N-nitroso group attached to two organic moieties, with nitrogen in the +3-oxidation state existing in resonance between nitroxide and diazo tautomers. Secondary amine-derived nitrosamines include N-nitrosodimethylamine, N-nitrosodiethylamine, N-nitrosomorpholine, N-nitrosopiperidine, and N-nitrosodiisopropylamine. Tertiary amine-derived nitrosamines include N-nitrosoethyl-isopropylamine and the more complex drug substance-related nitrosamines (NDSRIs), which are covalently incorporated into an active pharmaceutical ingredient's molecular scaffold, as seen with nitroso derivatives of valsartan, losartan, telmisartan, and varenicline. Low-molecular-weight volatile nitrosamines are amenable to gas chromatography, while higher-molecular-weight, non-volatile NDSRIs require liquid chromatography-based approaches.

2.2 Formation mechanism.

Nitrosamine formation requires a nitrosating agent and a secondary or tertiary amine. Nucleophilic attack of the amine's lone pair on an electrophilic nitrosating species, followed by deprotonation, yields the N-nitroso product. Nitrous acid and its anhydride, formed from nitrite under acidic conditions, are the principal nitrosating agents in pharmaceutical settings; nitrogen oxides from combustion or atmospheric sources can also participate. Formation kinetics are markedly enhanced by acidic pH (optimal around pH 1–3), elevated temperature, transition metal catalysis, and high nitrite or amine concentrations.

2.3 Sources of contamination

The predominant source is API synthesis, particularly steps using sodium nitrite for azide displacement in the presence of secondary amine intermediates (1,19). Dimethylamine-containing solvents such as dimethylformamide, dimethylacetamide, and N-methyl pyrrolidone pose risk both through residual traces and through recovered-solvent nitrite carryover. Contaminated raw materials, metal catalysts, and reagents introduce further risk. Excipients, though generally regarded as inert, may carry trace nitrite from their own manufacturing processes, and amino acid-derived excipients introduce additional amine functionality (8,9). Degradation related to storage is well known for ranitidine, where oxidative degradation under heat and humidity leads to the generation of the nitrosamine contaminant during shelf life rather than during manufacture. Packaging materials, including printing inks and elastomeric closures, can also contribute by migration of amine-containing components or photodegradation.

Table 1. Principal nitrosamine formation pathways in pharmaceuticals and associated mitigation strategies

3. TYPES OF NITROSAMINE IMPURITIES

3.1 Volatile nitrosamines

The most frequently detected volatile compounds include N-nitrosodimethylamine, N-nitrosodiethylamine, N-nitrosodiisopropylamine, N-Nitrosodibutylamine, N-nitroso-N-methyl-4-aminobutyric acid, N-nitrosoethyl-isopropylamine, N-nitrosomorpholine, and N-nitrosopiperidine. These are generally well suited to gas chromatography–mass spectrometry, with detection limits in the parts-per-billion to sub-parts-per-billion range.

3.2 API-specific nitrosamines (NDSRIs)

These compounds arise from nitrosation of amine functionality within the API structure itself, requiring dedicated method development because each NDSR is essentially unique to its parent drug. Sartan-derived NDSRIs and nitroso-varenicline are the best-characterized examples; their lower volatility necessitates liquid chromatography–tandem mass spectrometry rather than gas chromatography.

3.3 Comparative potency and acceptable intake

Acceptable intake values are derived from a benchmark dose producing a 10 percent increase in tumor incidence in animal studies, divided by default uncertainty factors, following ICH M7(R1) methodology. Values for commonly detected nitrosamines range from approximately 26.6 nanograms per day for the most potent compounds to 96 nanograms per day for less potent NDSRIs.

4. REGULATORY PERSPECTIVE AND GUIDELINES

4.1 United States Food and Drug Administration

The FDA has implemented a three-step process requiring manufacturers to conduct risk assessments of their products, perform confirmatory testing once risk has been identified, and report findings to the appropriate regulatory agencies (12,16). Its 2019 guidance document on control of nitrosamine impurities in drug products and subsequent guidance on acceptable intake limits of NDSRIs, remain foundational documents and are updated periodically as toxicological knowledge progresses.

4.2 European Medicines Agency

The EMA has a dedicated referral procedure and updated its guidance in July 2023 to include the carcinogenic potency categorisation approach and an enhanced Ames test for determination of acceptable intakes (3,14,15). The European Directorate for the Quality of Medicines and HealthCare has issued parallel scientific categorization frameworks.

4.3 ICH and international harmonization

The ICH M7(R1 guideline classifies nitrosamines as Class 1 impurities, and provides the internationally accepted methodology for risk assessment and derivation of acceptable intake, with further refinement ongoing through the M7(R2) process (12,13).

4.4 National authorities

Regulatory bodies such as the Therapeutic Goods Administration in Australia, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, the National Medical Products Administration in China, and ANVISA in Brazil, have issued guidance that is largely consistent with ICH principles, with some jurisdiction-specific requirements (7,8).

4.5 Acceptable intake concept

The acceptable intake is the highest daily exposure that is associated with an acceptable lifetime cancer risk, generally one additional case per 100,000 patients, and is determined by toxicological review, selection of a point of departure, application of uncertainty factors, and consideration of clinical utility (2,12).

Table 2. Acceptable intake limits for selected nitrosamines

4.6 Manufacturer obligations

Manufacturers need to carry out risk assessments throughout the product lifecycle, calculate patient exposure, compare exposure to relevant limits, put controls in place, carry out confirmatory testing and communicate findings to regulators (1).

5. ANALYTICAL DETECTION OF NITROSAMINE IMPURITIES

5.1 Analytical challenges

Nitrosamines must be quantified at concentrations several orders of magnitude below conventional impurity specifications, often in the low parts-per-billion range, where instrumental noise and matrix interference become proportionally significant (21,22). Complex pharmaceutical matrices introduce ionization suppression or enhancement in mass spectrometry, particularly from amine-containing APIs and quaternary ammonium excipients (4,22). Nitrosamines are also prone to artefactual formation during sample handling under acidic or oxidizing conditions, and to thermal or photochemical decomposition, requiring careful control of pH, temperature, and light exposure throughout sample preparation (4,20).

5.2 Sample preparation

Solid-phase extraction is the most widely used clean-up method, employing silica-based or polymeric sorbents to trap nitrosamines and eliminate polar excipients and API (21,22). Liquid-liquid extraction is used for aqueous or semi-solid matrices and protein precipitation is used for proteinaceous formulations. Headspace extraction, in which volatile nitrosamines partition into the vapor phase on heating, affords minimal sample handling and largely eliminates matrix effects for small molecule nitrosamines (21). Quality control measures include matrix blanks, solvent blanks, and recovery spiking, usually with a target of 80 to 110 percent recovery.

5.3 Chromatographic techniques.

Reversed-phase HPLC and UPLC using C18 or phenyl columns, with acidic aqueous-organic gradients, form the standard separation approach for non-volatile and polar nitrosamines. UPLC reduces analysis time from twenty to thirty minutes to eight to fifteen minutes but requires more rigorous system suitability protocols.

5.4 Hyphenated mass spectrometry.

LC-MS/MS is the current gold standard, using multiple reaction monitoring to eliminate interference from co-eluting matrix components; typical detection limits fall between 0.01 and 1 part per billion (7,12,27). GC-MS and GC-MS/MS provide orthogonal, volatility-based separation particularly suited to small-molecule nitrosamines (21). Supercritical fluid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry serve as supplementary techniques for compounds of intermediate polarity or particularly challenging matrices.

5.5 High-resolution mass spectrometry.

Quadrupole time-of-flight and orbital trap instruments provide exact mass measurement and structural elucidation capability, supporting suspect screening and non-targeted discovery of previously uncharacterized NDSRIs (4,5,6).

Table 3. Comparison of analytical techniques for nitrosamine detection

6. ANALYTICAL METHOD DEVELOPMENT AND VALIDATION

6.1 Method development strategy

Technique selection follows evaluation of volatility, polarity and ionizability, thermal stability, and fragmentation behavior of the target compound. Chromatographic optimization involves stationary phase chemistry, mobile phase pH and composition, and gradient design for LC methods and column phase, oven programming, and injector conditions for GC methods. Mass spectrometric optimization includes ionization source selection, parent and product ion selection, collision energy, and dwell time per transition.

6.2 Validation parameters

Method validation must follow ICH Q2(R2) and USP <1469>, with particular attention to specificity at trace levels, precision near the limit of quantitation, and demonstrated absence of artefactual formation. Internal standards, preferably stable isotope-labelled, are essential to correct for matrix effects and instrument drift.

Table 4. Key validation parameters for nitrosamine analytical methods